Skip to main content
Monica Dingle, Partner | Corporate/Commercial

Monica Dingle

Partner | Corporate/Commercial Fasken
Jurisdiction Ontario, 2011 | Québec, 2010
Language(s) French, English
Office(s) Montréal
Contact
Share
  • LinkedIn

Overview

Monica Dingle specializes in corporate and securities law. Her practice focuses on public company mergers and acquisitions and public financings.

Monica has been involved in numerous public and private company transactions, including acquisitions, sales and mergers. She has acted for issuers and underwriters in a wide range of private placements and prospectus offerings of Canadian entities.

A former Fasken articling student, Monica joined the team in 2010 as an associate before serving as Senior Legal Counsel for a leading manufacturer of high performance LED lighting solutions. She then acted as Director of Legal Affairs for a global independent investment management firm. Her corporate experience and understanding of business and commercial landscapes make her a key partner in resolving complex legal issues.

Monica is Fasken’s representative on the Board of Directors of The Canadian Club of Montreal, the leading forum in Montreal for leaders in business, politics, sports, culture and international affairs to state their positions on important current issues and trends.

In addition, she remains involved in her community with organizations that are close to her heart. She is currently a member of Board of Directors of the Fonderie Darling, a non-profit visual-arts venue in the Old Port of Montreal, and a member of the fundraising committee for Les Impatients, a non-profit organisation offering artistic workshops across Québec to individuals facing mental health challenges.

Monica holds a Commerce degree from Queen's University, a Civil Law degree from the University of Montreal and a Common Law degree from the University of Victoria.

Achievements

Client Work

  • Novacap supported Nuvei’s privatization by Advent, valued at US$6.3 billion, alongside Philip Fayer and CDPQ, [Deal - Novacap], Nuvei announced a going-private transaction valued at US$6.3 billion with Advent, alongside Philip Fayer, Novacap and CDPQ.
  • Allkem and Livent combine in an all-stock merger of equals to create a leading global integrated lithium chemicals producer valued at US$10.6 billion, [Deal - Allkem Ltd.], Allkem and Livent combine in an all-stock merger of equals.
  • H2O Innovation completed going-private transaction with Ember, Investissement Québec, Caisse de dépôt et placement du Québec and key executives of H2O Innovation, [Case - Investissement Québec], H2O Innovation completes going-private transaction with Ember, IQ, CDPQ and Key Executives.
  • Theratechnologies completes a US$25 million cross-border public offering and concurrent private placement with an innovative capital structure component, [Deal - Theratechnologies], Public offering of common shares and concurrent private placement completed by Theratechnologies.
  • Taiga Motors completes private placement of $40.15 million of secured convertible debentures, following an extensive review of various options and alternatives, [Deal - Taiga Motors Corporation Special Committee]
  • Noranda Income Fund completes going-private transaction with Glencore Canada Corporation, [Deal - Noranda Income Fund], Noranda Income Fund completes going-private transaction with Glencore Canada Corporation.
  • Issuance of C$1 billion senior notes by Fédération des Caisses Desjardins du Québec, [Deal - Desjardins Securities Inc.], On August 23, 2022, the Fédération des Caisses Desjardins du Québec issued $1 billion in Senior Notes.
  • Stifel Nicolaus Canada Inc. leads C$7.35 million unit offering for Else Nutrition Holdings Inc., [Deal - Stifel Nicolaus Canada Inc.]
  • Skye Bioscience signs arrangement agreement to acquire Emerald Health Therapeutics in a share-for-share transaction, [Deal - Skye Bioscience Inc], Emerald is a Vancouver-based Canadian licensed cannabis producer that is exiting the cannabis sector and pivoting into the pharmaceutical sector. Skye Bioscience is a US-based biopharmaceutical company focused on development of proprietary cannabinoid derivatives for medical treatment of various diseases.

Career & Education

Education

  • LLB, Law University of Victoria
  • LLB, Law Université de Montréal
  • B Comm, Commerce Queen's University

Community involvement

Memberships & Affiliations

  • Member, Quebec Bar
  • Member, Ontario Bar

Knowledge

Events

News

    Subscribe

    Receive email updates from our team

    Subscribe